Lewy body dementia, also known as dementia with Lewy bodies (DLB), is a type of progressive dementia that leads to a decline in thinking, reasoning, and autonomic function. It is one of the most common types of dementia, and is characterized by the presence of Lewy bodies, tiny deposits of the protein alpha-synuclein found in the neurons of the brain. These Lewy bodies are believed to contribute to changes in neurotransmission and the death of neurons. The cause of Lewy body dementia is still unknown, but there are several contributing factors, including age, genetics, and a history of traumatic brain injury. Scientists have also suggested that the condition may be linked to certain environmental toxins, including pesticides, herbicides, and heavy metals. The most common symptoms of Lewy body dementia are cognitive problems, including difficulties with memory, planning, problem solving, judgment, and decision-making. Changes in behavior are also common, such as depression, confusion, irritability, hallucinations, and delusions. Other symptoms can include visual problems, such as difficulty recognizing objects or the inability to read or write. Patients may also experience consistent low blood pressure, falls, unsteady gait, and rigidity of muscles in the trunk and limbs. Diagnosis of Lewy body dementia is made through a clinical evaluation by a doctor, who will take a detailed medical history and conduct a physical and neurological examination. Additionally, a PET scan or MRI can be used to look for the presence of Lewy bodies in the brain. Once diagnosed, there are currently no cures for Lewy body dementia. However, there are some treatments available to help manage the symptoms of this condition, such as using medications to control delusions or visual problems, cognitive behavioral therapy to address behavioral issues, and physical and occupational therapy to reduce mobility problems. It is important to recognize the signs and symptoms of Lewy body dementia so that an accurate diagnosis can be made and early treatment can be initiated. While there is currently no cure, with early diagnosis and treatment of this condition, patients can still enjoy a good quality of life.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States